ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare Tang Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FTAHHYPOTHETICAL MODEL
Since ’99
−83%
Expense Ratio
0.45%
placeholder
Holdings
100
cap-weighted
Inception
Jul 2019
placeholder
Full Sharpe
-0.20
Ann. Return (LS)
-4.1%
Ann. Volatility
20.5%
Max Drawdown
-90.5%
Test Sharpe ’19–26
-0.19
Test FF5 α (ann.)
1.1%
vs Fama-French 5
Test FF5 α t-stat
0.19
not significant
Monthly turnover
13%
of the long leg, per rebalance
Cumulative return (LS)
-83%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.16
what this fund holds
Long leg ann. return
4.6%
buyable, long-only
Long-short Sharpe
-0.20
requires shorting
Bottom bucket ann. return
8.7%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

100 of 100 · 100.0% of book
TickerCompanySectorMarket capWeight
1ONC
BEONE MEDICINES LTDHealthcare$34.68B
15.10%
2INCY
INCYTE CORPHealthcare$23.42B
10.20%
3GH
GUARDANT HEALTH INCHealthcare$20.67B
9.00%
4BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
6.94%
5AXSM
AXSOME THERAPEUTICS INCHealthcare$11.84B
5.15%
6IMVT
IMMUNOVANT INCHealthcare$8.27B
3.60%
7LQDA
LIQUIDIA CORPHealthcare$7.11B
3.09%
8SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
2.76%
9BLLN
BILLIONTOONE INCHealthcare$5.99B
2.61%
10TXG
10X GENOMICS INCHealthcare$5.55B
2.42%
11CAI
CARIS LIFE SCIENCES INCHealthcare$4.66B
2.03%
12ALHC
ALIGNMENT HEALTHCARE INCHealthcare$4.26B
1.85%
13DYN
DYNE THERAPEUTICS INCHealthcare$3.92B
1.71%
14CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
1.68%
15PBLS
PARABILIS MEDICINES INCHealthcare$3.51B
1.53%
16WRBY
WARBY PARKER INCHealthcare$3.24B
1.41%
17KOD
KODIAK SCIENCES INCHealthcare$2.67B
1.16%
18TMDX
TRANSMEDICS GROUP INCHealthcare$2.56B
1.11%
19IMNM
IMMUNOME INCHealthcare$2.53B
1.10%
20SLS
SELLAS LIFE SCIENCES GROUP INCHealthcare$2.45B
1.07%
21PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
0.98%
22PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.86%
23AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.86%
24OCUL
OCULAR THERAPEUTIX INCHealthcare$1.96B
0.85%
25URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.85%
26DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.84%
27ZBIO
ZENAS BIOPHARMA INCHealthcare$1.86B
0.81%
28ALMR
ALAMAR BIOSCIENCES INCHealthcare$1.80B
0.78%
29BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.75%
30TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.75%
31ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.73%
32CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.73%
33MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.63%
34OMDA
OMADA HEALTH INCHealthcare$1.41B
0.61%
35AKTS
AKTIS ONCOLOGY INCHealthcare$1.33B
0.58%
36INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.56%
37AVLN
AVALYN PHARMA INCHealthcare$1.25B
0.55%
38IRMD
IRADIMED CORPHealthcare$1.24B
0.54%
39NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.49%
40WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.49%
41PRCT
PROCEPT BIOROBOTICS CORPHealthcare$1.09B
0.48%
42FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.44%
43ANRO
ALTO NEUROSCIENCE INCHealthcare$967M
0.42%
44ANNX
ANNEXON INCHealthcare$950M
0.41%
45LBRX
LB PHARMACEUTICALS INCHealthcare$901M
0.39%
46TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.38%
47PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.38%
48REPL
REPLIMUNE GROUP INCHealthcare$859M
0.37%
49SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.37%
50AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.36%
51CADL
CANDEL THERAPEUTICS INCHealthcare$746M
0.32%
52AURA
AURA BIOSCIENCES INCHealthcare$723M
0.31%
53SGP
SPYGLASS PHARMA INCHealthcare$661M
0.29%
54ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.28%
55TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.27%
56STTK
SHATTUCK LABS INCHealthcare$577M
0.25%
57IMMX
IMMIX BIOPHARMA INCHealthcare$558M
0.24%
58VSTM
VERASTEM INCHealthcare$530M
0.23%
59ZURA
ZURA BIO LTDHealthcare$518M
0.23%
60NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.22%
61PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.20%
62BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.19%
63TENX
TENAX THERAPEUTICS INCHealthcare$420M
0.18%
64CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.18%
65MOBI
MOBIA MEDICAL INCHealthcare$404M
0.18%
66FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
0.16%
67ELMD
ELECTROMED INCHealthcare$349M
0.15%
68CV
CAPSOVISION INCHealthcare$335M
0.15%
69CARL
CARLSMED INCHealthcare$317M
0.14%
70SGHT
SIGHT SCIENCES INCHealthcare$274M
0.12%
71CNXU
CONEXEU SCIENCES INCHealthcare$263M
0.11%
72QTTB
Q32 BIO INCHealthcare$255M
0.11%
73SRZN
SURROZEN INCHealthcare$255M
0.11%
74GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.10%
75UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.10%
76KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.09%
77KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.09%
78RNA
ATRIUM THERAPEUTICS INCHealthcare$208M
0.09%
79IMUX
IMMUNIC INCHealthcare$207M
0.09%
80DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.09%
81AMWL
AMERICAN WELL CORPHealthcare$199M
0.09%
82TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.09%
83ACOG
ALPHA COGNITION INCHealthcare$185M
0.08%
84ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.07%
85OWLT
OWLET INCHealthcare$162M
0.07%
86PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.06%
87VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.06%
88CUE
CUE BIOPHARMA INCHealthcare$126M
0.05%
89SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.05%
90VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.04%
91LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INCHealthcare$91M
0.04%
92RLYB
RALLYBIO CORPHealthcare$87M
0.04%
93CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.04%
94NRXS
NEURAXIS INCHealthcare$84M
0.04%
95NMAD
NOMAD POWER SOLUTIONS INCHealthcare$72M
0.03%
96EDSA
EDESA BIOTECH INCHealthcare$59M
0.03%
97INKT
MINK THERAPEUTICS INCHealthcare$53M
0.02%
98XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.02%
99MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.02%
100EXOZ
EXOZYMES INCHealthcare$51M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $229.72B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

100 classified
Value
Blend
Growth
Large
Mid
Small
12%2
4%2
36%8
3%5
8%10
8%9
4%27
3%15
1%9

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 78% toward Large, 67% toward Growth. +21% unclassified (13 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt78% → Large
SmallLarge
Value ↔ growth tilt67% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 100 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 100 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
2.1 (95% CI 1.5-2.9)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
20.6%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
2.14x
over
parametric
1.85x
within
cornish fisher
2.00x
over

The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.14 (fail) but Gaussian VaR gives 1.85 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2009
Before publication (pre-2009)
-0.43
Sharpe · -8.5% p.a.
January 1999December 2009 · 132 mo
Since publication
-0.06
Sharpe · -1.3% p.a.
January 2010July 2026 · 199 mo
Change in Sharpe+0.37Sharpe strengthened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
42%
11 of 26 3-year windows made money
Worst window
-1.17
Sharpe, January 2021 – December 2023
January 1999July 2026
Median Sharpe
-0.08
Dispersion
0.47
Best window
0.48

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.41.9%22.2%
3 yearsp.a.8.2%4.0%
5 yearsp.a.-8.9%-10.0%
10 yearsp.a.0.9%-5.4%
Since inceptionp.a.0.6%-6.1%
Calendar years
YearLong legLong-short
20267 mo13.7%12.2%
202533.8%19.8%
2024-9.5%-13.3%
20230.2%9.5%
2022-33.1%-25.0%
2021-46.7%-57.6%
202057.8%43.3%
201924.3%1.9%
2018-13.2%-18.6%
201728.7%8.8%
2016-18.5%-11.3%
20150.9%-5.4%
201439.7%15.9%
201343.5%-4.5%
201230.8%13.7%
20115.2%-7.5%
201016.9%8.6%
200913.8%-5.9%
2008-29.0%7.8%
20072.4%3.4%
20066.3%2.0%
2005-1.5%-9.9%
2004-1.1%-0.4%
200332.1%-8.1%
2002-41.1%-21.4%
2001-28.8%-17.7%
2000-17.5%-36.9%
19995.7%-12.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FTAH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-07-02 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$229.72B

Methodology

The Foundry Healthcare Tang Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Tang signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.